MGNX - マクロジェニクス （MacroGenics Inc.） マクロジェニクスMGNXのチャート
MGNXの企業情報
| symbol | MGNx |
|---|---|
| 会社名 | MacroGenics Inc （マクロジェニクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 マクロジェニックス(MacroGenics Inc.)は臨床段階のバイオ医薬品会社である。同社は癌と自己免疫疾患及び感染症の治療用のモノクローナル抗体ベースの治療薬の発見と開発を中心とする。同社は抗体ベースの技術プラットフォームを使用して、また他の生物医薬品企業と協力して治療薬候補を開発する。ヒトの臨床試験では、主に技術プラットフォームを使用して作成された各タイプの癌の治療薬として製品候補のパイプラインがある。臨床製品候補であるmargetuximabは、Fc最適化プラットフォームを使用して強化された。同社はまた、免疫調節タンパク質のB7ファミリーのタンパク質であるB7-H3を標的とするいくつかの製品候補を開発している。同社の製品候補には、enoblituzumabおよびMGD009、MGC018、MGD006（フロテツズマブ）、MGD007、MGD011（duvortuxizumab）、PF-06671008およびMGD010も含まれる。 マクロジェニクスは米国のバイオ医薬品企業。癌や自己免疫疾患の治療薬としてモノクロ―ナル抗体の開発を手掛ける。乳癌、食道癌、膀胱癌の治療薬Margetuximab、黒色腫、膠芽細胞腫、前立腺癌、乳癌などの治療薬MGA271や、血液癌の治療薬MGD006、結腸直腸癌の治療薬MGD007、1型糖尿病治療薬Teplizumabの開発を行う。 MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc. |
| 本社所在地 | 9704 Medical Center Drive Rockville MD 20850 USA |
| 代表者氏名 | Paulo F. Costa パウロF.コスタ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 301-251-5172 |
| 設立年月日 | 36739 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 330人 |
| url | www.macrogenics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mgnx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -31.49200 |
| 終値（lastsale） | 20.19 |
| 時価総額（marketcap） | 852772803.15 |
| 時価総額 | 時価総額（百万ドル） 791.52860 |
| 売上高 | 売上高（百万ドル） 177.55100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 490.63460 |
| 当期純利益 | 当期純利益（百万ドル） -34.09600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 MacroGenics Inc revenues increased from $3.7M to $23.5M. Net loss increased 18% to $92.8M. Revenues reflect Revenue from collaborative agreements increase from $2.4M to $23.1M. Higher net loss reflects Research&development-Bal Val increase of 47% to $94M (expense) General and administrative - Balancing v increase of 34% to $16.5M (expense). |
MGNXのテクニカル分析
MGNXのニュース
MacroGenics Inc. (MGNX) produces promising results 2022/12/29 14:00:00 US Post News
MacroGenics Inc. (NASDAQ:MGNX) closed Wednesday at $5.69 per share, up from $5.62 a day earlier. While MacroGenics Inc. has overperformed by 1.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MGNX fell by -65.01%, with highs and lows ranging from $17.30 to $2.13, whereas the simple […]
What Could Change After MacroGenics Inc. (NASDAQ: MGNX) Gains 64.14% From The High-Point? 2022/12/24 19:00:00 Marketing Sentinel
MacroGenics Inc. (NASDAQ:MGNX)’s traded shares stood at 0.49 million during the last session, with the company’s beta value hitting 2.07. At the close of trading, the stock’s price was $5.94, to imply an increase of 0.68% or $0.04 in intraday trading. The MGNX share’s 52-week high remains $17.66, putting it -197.31% down since that peak … What Could Change After MacroGenics Inc. (NASDAQ: MGNX) Gains 64.14% From The High-Point? Read More »
MacroGenics Inc. (NASDAQ:MGNX) Shares Rebounded 65.48% From Their Lows – But Can They Continue? 2022/11/25 16:00:00 Marketing Sentinel
In last trading session, MacroGenics Inc. (NASDAQ:MGNX) saw 1.39 million shares changing hands with its beta currently measuring 2.07. Company’s recent per share price level of $6.17 trading at -$0.01 or -0.16% at ring of the bell on the day assigns it a market valuation of $384.02M. That closing price of MGNX’s stock is at … MacroGenics Inc. (NASDAQ:MGNX) Shares Rebounded 65.48% From Their Lows – But Can They Continue? Read More »
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56% 2022/11/23 15:56:41 Benzinga
Mizuho cut the price target on Baidu, Inc. (NASDAQ: BIDU ) from $200 to $180. Mizuho analyst James Lee maintained the stock with a Buy rating. Baidu shares rose 2.5% to trade at $97.49 on Wednesday. Citigroup slashed the price target on MacroGenics, Inc. (NASDAQ: MGNX ) from … Full story available on Benzinga.com
MacroGenics cut to Neutral at Citi, Guggenheim upgrades 2022/11/23 14:31:36 Seeking Alpha
MacroGenics (MGNX) has garnered attention on Wall Street this week, with Citi downgrading the commercial-stage biotech on Wednesday to Neutral from Buy after an upgrade from Guggenheim…
Small Cap Stock MacroGenics Inc. (MGNX) Is A Buy – Analysts 2022/08/10 11:00:00 Marketing Sentinel
MacroGenics Inc. (NASDAQ:MGNX) has a beta value of 2.06 and has seen 1.3 million shares traded in the last trading session. The company, currently valued at $280.81M, closed the last trade at $5.10 per share which meant it gained $0.55 on the day or 12.09% during that session. The MGNX stock price is -450.78% off … Small Cap Stock MacroGenics Inc. (MGNX) Is A Buy – Analysts Read More »
MacroGenics Jumps Biotech Layoff Bandwagon, Cuts 15% Of Workforce 2022/08/09 19:23:30 Benzinga
MacroGenics Inc (NASDAQ: MGNX ) announced a corporate restructuring involving a 15% workforce reduction , closure of an R&D facility, and closure of a manufacturing site. After discontinuing a Phase 2 study for enoblituzumab , a program that was upside to estimates, the company''s pipeline efforts are more narrowly focused on MGC018, lorigerlimab, … Full story available on Benzinga.com
MacroGenics (MGNX) Q2 2022 Earnings Call Transcript 2022/08/09 04:30:33 The Motley Fool
MGNX earnings call for the period ending June 30, 2022.
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2022 Results Earnings Call Transcript 2022/08/09 03:05:04 Seeking Alpha
MacroGenics, Inc. (NASDAQ:NASDAQ:MGNX) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Chris James - VP, IR and Corporate Communications Scott Koenig -…
Macrogenics: Q2 Earnings Insights 2022/08/08 21:14:45 Benzinga
Macrogenics (NASDAQ: MGNX ) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Macrogenics beat estimated earnings by 30.93%, reporting an EPS … Full story available on Benzinga.com
MacroGenics Inc. (NASDAQ: MGNX): Can A Stock That’s Down -79.25% YTD Still Be Considered In Loss Territory? 2022/06/24 11:00:00 Marketing Sentinel
During the last session, MacroGenics Inc. (NASDAQ:MGNX)’s traded shares were 1.2 million, with the beta value of the company hitting 2.22. At the end of the trading day, the stock’s price was $3.33, reflecting an intraday gain of 3.10% or $0.1. The 52-week high for the MGNX share is $29.16, that puts it down -775.68 … MacroGenics Inc. (NASDAQ: MGNX): Can A Stock That’s Down -79.25% YTD Still Be Considered In Loss Territory? Read More »
Why MacroGenics Stock Is Skyrocketing Today 2022/06/21 17:10:50 The Motley Fool
Investors like that a key insider is buying shares of the biotech.
45 Stocks Moving In Tuesday''s Mid-Day Session 2022/06/21 16:03:56 Benzinga
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY ) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. Valneva SE (NASDAQ: VALN ) gained 79.4% to $24.60. Pfizer will invest €90.5 million ($95 million) for an 8.1% stake in Valneva, as the companies updated the terms of agreement for Lyme disease vaccine candidate VLA15. BlackSky Technology Inc. (NYSE: BKSY ) shares jumped 26.4% to $2.5650. BlackSky won a 5-year joint Artificial Intelligence Center contract for AI data readiness. Phoenix New Media Limited (NYSE: FENG ) gained 26.2% to $5.88. Argo Blockchain plc (NASDAQ: ARBK ) jumped 23.9% to $4.66. PermRock Royalty Trust (NYSE: PRT ) gained 22.3% to $8.61. Revlon, Inc. (NYSE: REV ) rose 22.3% to $4.56. Revlon shares jumped 91% on Friday following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. Hallador Energy Company (NASDAQ: HNRG ) gained 20.8% to $7.31. MacroGenics, Inc.
MacroGenics Inc. (MGNX): Worth A Little Bit At $2.80 2022/06/11 15:30:00 Stocks Register
MacroGenics Inc. (NASDAQ:MGNX) concluded the trading at $2.80 on Friday, June 10, with a fall of -8.79% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.07 and 5Y monthly beta was reading 2.11 with its price kept floating in the range … MacroGenics Inc. (MGNX): Worth A Little Bit At $2.80 Read More »
Advanced Cervical Cancer Clinical Trial Pipeline Analysis Research Report 2022 by DelveInsight 2022/06/08 17:00:00 Benzinga
New York, USA, June 08, 2022 (GLOBE NEWSWIRE) -- Advanced Cervical Cancer Clinical Trial Pipeline Analysis Research Report 2022 by DelveInsight As per DelveInsight, recent advances in Cervical Cancer have provided new options for treating patients with advanced forms of the disease, fulfilling a significant unmet medical need. Advanced Cervical Cancer Pipeline involves 75+ key companies continuously working towards developing 75+ Advanced Cervical Cancer treatment therapies. DelveInsight''s '' Advanced Cervical Cancer Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Advanced Cervical Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Advanced Cervical Cancer pipeline domain. Key Takeaways from the Advanced Cervical Cancer Pipeline Report DelveInsight''s Advanced Cervical Cancer Pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.